GlassScriptPhysician profile
Christopher Thomas Messitt
NPI 1578536991
$7,798.97
in general payments reported to CMS, 2019-2025
35 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $210 · 2021: $1,255 · 2022: $1,078 · 2023: $2,094 · 2024: $2,694 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,924.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,709.61 | 2021-2025 | |
| Novo Nordisk INC | $1,288.27 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $867.19 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $451.21 | 2019-2024 | Trintellix |
| Pfizer INC. | $449.00 | 2019-2024 | |
| Lilly USA, LLC | $400.29 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $340.13 | 2021-2024 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.04 | 2019-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $204.11 | 2021-2024 | Rexulti |
| Amgen INC. | $180.09 | 2021-2023 | Evenity, Prolia |
| Exact Sciences Corporation | $170.18 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $162.15 | 2019-2024 | Veozah |
| Currax Pharmaceuticals LLC | $141.67 | 2021-2023 | Onzetra Xsail, Contrave |
| Corium, LLC | $125.56 | 2023-2024 | Azstarys |
| Axsome Therapeutics, INC. | $104.86 | 2023-2024 | Auvelity |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $103.40 | 2019-2021 | |
| Ibsa Pharma INC. | $98.81 | 2019-2024 | Licart, Tirosint |
| Idorsia Pharmaceuticals US INC | $97.56 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $91.76 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $85.50 | 2024 | Voquezna |
| Amarin Pharma, INC. | $78.24 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $74.07 | 2022 | |
| Abbott Laboratories | $55.25 | 2024 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $48.89 | 2021 | |
| Sanofi-Aventis U.S. LLC | $40.15 | 2019-2022 | |
| Eisai INC. | $25.24 | 2021 | |
| Seqirus USA INC | $22.89 | 2024 | Fluad, Flucelvax |
| Amryt Pharma Holdings LTD | $19.94 | 2021 | |
| Sanofi Pasteur INC. | $19.44 | 2023 | |
| Alfasigma USA, INC. | $16.85 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.42 | 2019 | |
| Azurity Pharmaceuticals, INC. | $15.79 | 2023 | Adthyza |
| Novartis Pharmaceuticals Corporation | $14.89 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.72 | 2019 | |
| Allergan, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Messitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.